

Bankole A Johnson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6655031/publications.pdf>

Version: 2024-02-01

41
papers

5,419
citations

236925

25
h-index

276875

41
g-index

43
all docs

43
docs citations

43
times ranked

2923
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence. JAMA - Journal of the American Medical Association, 2006, 295, 2003.	7.4	1,680
2	Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet, The, 2003, 361, 1677-1685.	13.7	718
3	Topiramate for Treating Alcohol Dependence<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2007, 298, 1641.	7.4	490
4	Ondansetron for Reduction of Drinking Among Biologically Predisposed Alcoholic Patients. JAMA - Journal of the American Medical Association, 2000, 284, 963.	7.4	385
5	Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings. Biochemical Pharmacology, 2008, 75, 34-56.	4.4	246
6	Topiramate in the New Generation of Drugs: Efficacy in the Treatment of Alcoholic Patients. Current Pharmaceutical Design, 2010, 16, 2103-2112.	1.9	241
7	Pharmacogenetic Approach at the Serotonin Transporter Gene as a Method of Reducing the Severity of Alcohol Drinking. American Journal of Psychiatry, 2011, 168, 265-275.	7.2	180
8	Percentage of Subjects With No Heavy Drinking Days: Evaluation as an Efficacy Endpoint for AlcoholClinical Trials. Alcoholism: Clinical and Experimental Research, 2010, 34, 2022-2034.	2.4	156
9	Oral Topiramate Reduces the Consequences of Drinking and Improves theQuality of Life of Alcohol-Dependent Individuals. Archives of General Psychiatry, 2004, 61, 905.	12.3	154
10	Medication Treatment of Different Types of Alcoholism. American Journal of Psychiatry, 2010, 167, 630-639.	7.2	135
11	Topiramate for the Treatment of Cocaine Addiction. JAMA Psychiatry, 2013, 70, 1338.	11.0	110
12	Improvement of Physical Health and Quality of Life of Alcohol-Dependent Individuals With Topiramate Treatment<subtitle>US Multisite Randomized Controlled Trial</subtitle>. Archives of Internal Medicine, 2008, 168, 1188.	3.8	109
13	Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials. JAMA Psychiatry, 2019, 76, 374.	11.0	77
14	Progress in the Development of Topiramate for Treating Alcohol Dependence: From a Hypothesis to a Proof-of-Concept Study. Alcoholism: Clinical and Experimental Research, 2004, 28, 1137-1144.	2.4	72
15	Dose-Ranging Kinetics and Behavioral Pharmacology of Naltrexone and Acamprostate, Both Alone and Combined, in Alcohol-Dependent Subjects. Journal of Clinical Psychopharmacology, 2003, 23, 281-293.	1.4	61
16	Topiramate-induced neuromodulation of corticoâmesolimbic dopamine function: A new vista for the treatment of comorbid alcohol and nicotine dependence?. Addictive Behaviors, 2004, 29, 1465-1479.	3.0	59
17	A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. International Journal of Neuropsychopharmacology, 2008, 11, 1-14.	2.1	58
18	Ondansetron Reduces Mood Disturbance Among Biologically Predisposed, Alcohol-Dependent Individuals. Alcoholism: Clinical and Experimental Research, 2003, 27, 1773-1779.	2.4	54

#	ARTICLE	IF	CITATIONS
19	Topiramate reduces the harm of excessive drinking: implications for public health and primary care. <i>Addiction</i> , 2006, 101, 1561-1568.	3.3	44
20	Analyzing repeated measures semi-continuous data, with application to an alcohol dependence study. <i>Statistical Methods in Medical Research</i> , 2016, 25, 133-152.	1.5	42
21	An overview of the development of medications including novel anticonvulsants for the treatment of alcohol dependence. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 1943-1955.	1.8	36
22	Can serotonin transporter genotype predict serotonergic function, chronicity, and severity of drinking?. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 209-216.	4.8	36
23	Effects of isradipine on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition. <i>Psychopharmacology</i> , 2005, 178, 296-302.	3.1	30
24	Combining Ondansetron and Naltrexone Treats Biological Alcoholics: Corroboration of Self-Reported Drinking by Serum Carbohydrate Deficient Transferrin, A Biomarker. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 847-849.	2.4	26
25	Naltrexone long-acting formulation in the treatment of alcohol dependence. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 741-9.	2.0	26
26	Uses of topiramate in the treatment of alcohol dependence. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 751-758.	2.8	21
27	Topiramate's effects on cocaine-induced subjective mood, craving and preference for money over drug taking. <i>Addiction Biology</i> , 2013, 18, 405-416.	2.6	21
28	Effects of Isradipine on Cocaine-Induced Subjective Mood. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 180-191.	1.4	18
29	Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine's subjective and reinforcing effects. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 203-213.	2.1	17
30	Kinetic and cardiovascular comparison of immediate-release isradipine and sustained-release isradipine among non-treatment-seeking, cocaine-dependent individuals. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 15-20.	4.8	16
31	The role of serotonergic agents as treatments for alcoholism. <i>Drugs of Today</i> , 2003, 39, 665.	2.4	12
32	Cumulative Proportion of Responders Analysis (CPRA) as a Tool to Assess Treatment Outcome in Alcohol Clinical Trials. <i>Journal of Studies on Alcohol and Drugs</i> , 2014, 75, 335-346.	1.0	11
33	Kinetic and cardiovascular effects of acute topiramate dosing among non-treatment-seeking, methamphetamine-dependent individuals. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 455-461.	4.8	10
34	The efficacy of a low dose combination of topiramate and naltrexone on ethanol reinforcement and consumption in rat models. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 116, 107-115.	2.9	9
35	Advances in Medications and Tailoring Treatment for Alcohol Use Disorder. , 2015, 37, 15-28.		8
36	Should the Reorganization of Addiction-Related Research Across All the National Institutes of Health Be Structural?-The Devil Is Truly in the Details. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 572-580.	2.4	7

#	ARTICLE	IF	CITATIONS
37	In silico Models of Alcohol Dependence and Treatment. <i>Frontiers in Psychiatry</i> , 2012, 3, 4.	2.6	6
38	Toward Rational, Evidence-Based, and Clinically Relevant Measures to Determine Improvement Following Treatment for Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 703-707.	2.4	5
39	How Should Addiction-Related Research at the National Institutes of Health be Reorganized?. <i>Frontiers in Psychiatry</i> , 2011, 2, 2.	2.6	2
40	<sc>FDA</sc> and <sc>EMA</sc> Need Homology on Alcohol Outcome Measures<i>â€”Semper: Simplicitas est purius modum</i>. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1383-1384.	2.4	1
41	A randomized, double-blind, placebo-controlled trial of ondansetron for the treatment of cocaine use disorder with post hoc pharmacogenetic analysis. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109074.	3.2	1